Sander J. H. Van Deventer

Sander J. H. Van Deventer's AcademicInfluence.com Rankings

Medical

#2023

World Rank

#2415

Historical Rank

Gastroenterology

#32

World Rank

#34

Historical Rank

medical Degrees

Download Badge

Medical

Sander J. H. Van Deventer's Degrees

Doctorate Medicine University of Amsterdam
PhD Gastroenterology University of Amsterdam

Why Is Sander J. H. Van Deventer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sander J. H. Van Deventer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Infliximab for the treatment of fistulas in patients with Crohn's disease. (1999) (2254)
Infliximab maintenance therapy for fistulizing Crohn's disease. (2004) (2059)
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. (1997) (1359)
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). (1995) (1074)
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. (1999) (1065)
Natalizumab induction and maintenance therapy for Crohn's disease. (2005) (887)
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. (1999) (757)
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. (2003) (747)
Activation of coagulation after administration of tumor necrosis factor to normal subjects. (1990) (710)
A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. (2006) (694)
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease (2002) (592)
Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. (1994) (556)
Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. (1997) (504)
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. (1990) (486)
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. (1994) (452)
Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets (2003) (408)
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees (1994) (408)
A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. (1999) (388)
Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia (1996) (388)
Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. (2002) (386)
Leptin is a growth factor for colonic epithelial cells. (2001) (374)
Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E1 and E2 production by intestinal myofibroblasts (2003) (347)
Pathogenesis of disseminated intravascular coagulation in sepsis. (1993) (346)
Efficacy and long term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open label trial (2012) (345)
Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. (2004) (323)
Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. (2007) (320)
Proinflammatory Effects of IL-10 During Human Endotoxemia1 (2000) (297)
Cloning and characterization of cDNAs for murine macrophage inflammatory protein 2 and its human homologues (1990) (294)
Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. (2000) (281)
Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. (2000) (276)
Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood (1994) (276)
Sonic hedgehog regulates gastric gland morphogenesis in man and mouse. (2001) (268)
Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. (2003) (262)
Fibrinolytic response to tumor necrosis factor in healthy subjects (1991) (260)
HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis (1999) (252)
Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barrett's esophagus. (2005) (249)
Linkage of inflammatory bowel disease to human chromosome 6p. (1999) (245)
Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. (2004) (241)
Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. (1996) (240)
Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease (2001) (232)
The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. (2000) (228)
Depletion of Alveolar Macrophages Exerts Protective Effects in Pulmonary Tuberculosis in Mice1 (2001) (224)
Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. (1997) (221)
Postoperative ileus is maintained by intestinal immune infiltrates that activate inhibitory neural pathways in mice. (2003) (216)
Distribution and Kinetics of Lipoprotein-Bound Endotoxin (2001) (211)
Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. (2001) (207)
Hand-Assisted Laparoscopic Versus Open Restorative Proctocolectomy With Ileal Pouch Anal Anastomosis: A Randomized Trial (2004) (204)
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ (2002) (201)
Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees (1994) (197)
Computed tomographic colonography compared with colonoscopy in patients at increased risk for colorectal cancer. (2004) (194)
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. (2000) (189)
Tumour necrosis factor and Crohn's disease. (1997) (184)
Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. (1994) (180)
Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. (1998) (180)
Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. (2005) (178)
The Pathogenicity of Cytomegalovirus in Inflammatory Bowel Disease: A Systematic Review and Evidence-based Recommendations for Future Research (2004) (177)
Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus. (2005) (173)
Interleukin-6 mediates host defense responses induced by abdominal surgery. (1993) (170)
Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn’s disease (2006) (168)
Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia1 (2002) (166)
Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. (1997) (165)
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease (2005) (164)
Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease (2007) (162)
Endotoxin, cytokines, and endotoxin binding proteins in obstructive jaundice and after preoperative biliary drainage (2000) (160)
Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. (2006) (159)
Glucocorticoids cause rapid dissociation of a T‐cell‐receptor‐associated protein complex containing LCK and FYN (2006) (157)
Cytokines and anticytokines in the pathogenesis of sepsis. (1999) (156)
Clinical relevance of antibiotic-induced endotoxin release (1994) (155)
A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein. (2000) (155)
Increased expression of DC‐SIGN+IL‐12+IL‐18+ and CD83+IL‐12–IL‐18– dendritic cell populations in the colonic mucosa of patients with Crohn's disease (2003) (153)
Adenosine triphosphate‐binding cassette transporter genes up‐regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs (2012) (148)
High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. (1995) (141)
Molecular therapy for obesity and diabetes based on a long‐term increase in hepatic fatty‐acid oxidation (2011) (139)
Sonic hedgehog expression correlates with fundic gland differentiation in the adult gastrointestinal tract (2002) (138)
Cytokine production in a model of wound healing: the appearance of MIP-1, MIP-2, cachectin/TNF and IL-1. (1990) (136)
Recurrent Venous Thrombosis and Markers of Inflammation (2000) (134)
IC14, an Anti-CD14 Antibody, Inhibits Endotoxin-Mediated Symptoms and Inflammatory Responses in Humans1 (2001) (134)
A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis (2004) (130)
Altered Expression of Interferon‐&ggr; and Interleukin‐4 in Inflammatory Bowel Disease (1998) (126)
Pharmacokinetics of 6-Mercaptopurine in Patients with Inflammatory Bowel Disease: Implications for Therapy (2004) (126)
Preoperative endoscopic drainage for malignant obstructive jaundice (1994) (125)
p38 Mitogen-Activated Protein Kinase Inhibition Increases Cytokine Release by Macrophages In Vitro and During Infection In Vivo (2001) (124)
IL-18 Improves the Early Antimicrobial Host Response to Pneumococcal Pneumonia (2002) (123)
Lipopolysaccharide Is Transferred from High-Density to Low-Density Lipoproteins by Lipopolysaccharide-Binding Protein and Phospholipid Transfer Protein (2005) (123)
Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. (1994) (123)
Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis (2002) (123)
Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. (1993) (122)
Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. (2010) (117)
Antibiotic-induced endotoxin release in patients with gram-negative urosepsis: a double-blind study comparing imipenem and ceftazidime. (1995) (117)
Arginine deficiency affects early B cell maturation and lymphoid organ development in transgenic mice. (2002) (116)
Factor VIIa/Tissue Factor-induced Signaling via Activation of Src-like Kinases, Phosphatidylinositol 3-Kinase, and Rac* (2000) (115)
Mast cell degranulation during abdominal surgery initiates postoperative ileus in mice. (2004) (115)
TNF-α Compensates for the Impaired Host Defense of IL-1 Type I Receptor-Deficient Mice During Pneumococcal Pneumonia1 (2001) (115)
Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum (1995) (114)
Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. (2007) (110)
Soluble granzymes are released during human endotoxemia and in patients with severe infection due to gram-negative bacteria. (2000) (109)
Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation. (1997) (108)
Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. (1992) (108)
Intestinal permeability, circulating endotoxin, and postoperative systemic responses in cardiac surgery patients. (1996) (107)
Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice. (2007) (106)
CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. (1997) (106)
Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis. (2000) (103)
AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington’s Disease Minipig Model (2018) (102)
CpG Oligodeoxynucleotides Enhance Host Defense during Murine Tuberculosis (2002) (102)
Elevated Chemokine Concentrations in Sera of Human Immunodeficiency Virus (HIV)-Seropositive and HIV-Seronegative Patients with Tuberculosis: a Possible Role for Mycobacterial Lipoarabinomannan (1999) (100)
A Double-blind, Placebo-controlled, Randomized Study of Infliximab in Primary Sclerosing Cholangitis (2008) (100)
Interleukin 1 beta is expressed predominantly by enterocytes in experimental colitis. (1991) (98)
Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection. (1993) (98)
Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis. (1999) (96)
Up-regulation of HIV coreceptors CXCR4 and CCR5 on CD4(+) T cells during human endotoxemia and after stimulation with (myco)bacterial antigens: the role of cytokines. (2000) (95)
Distribution and Kinetics of Lipoprotein-Bound Lipoteichoic Acid (2003) (94)
Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease. (2005) (92)
Differential Effects of Reconstituted High-density Lipoprotein on Coagulation, Fibrinolysis and Platelet Activation during Human Endotoxemia (1997) (92)
Hapten‐induced colitis associated with maintained Th1 and inflammatory responses in IFN‐γ receptor‐deficient mice (2000) (90)
Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease (2016) (89)
IL-18-Binding Protein Expression by Endothelial Cells and Macrophages Is Up-Regulated During Active Crohn’s Disease1 (2002) (88)
Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. (2009) (87)
Experimental pneumococcal meningitis in mice: a model of intranasal infection. (2001) (87)
Interleukin-12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees. (1999) (86)
Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure. (2003) (85)
Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis. (1998) (85)
Endoscopy in inflammatory bowel diseases. (2004) (84)
Normalization of plasma vitamin B12 concentration by intranasal hydroxocobalamin in vitamin B12-deficient patients. (1997) (84)
Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease (1998) (83)
Cytokine and cytokine receptor polymorphisms in infectious disease (2000) (82)
Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. (2003) (82)
Chemokine Receptor CXCR3 Expression in Inflammatory Bowel Disease (2001) (82)
Peritoneal cytokine release after elective gastrointestinal surgery and postoperative complications. (1998) (82)
Expression and Activation of NF-κB in the Antrum of the Human Stomach (2000) (81)
Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. (2007) (81)
Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. (2002) (80)
Mice Lacking the Multidrug Resistance Protein 1 Are Resistant to Streptococcus pneumoniae-Induced Pneumonia1 (2001) (80)
A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. (2005) (79)
The CXC Chemokines Gamma Interferon (IFN-γ)-Inducible Protein 10 and Monokine Induced by IFN-γ Are Released during Severe Melioidosis (2000) (75)
Effects on leukocytes after injection of tumor necrosis factor into healthy humans. (1992) (75)
Induction of Antigen-Specific Tolerance by Oral Administration of Lactococcus lactis Delivered Immunodominant DQ8-Restricted Gliadin Peptide in Sensitized Nonobese Diabetic Ab° Dq8 Transgenic Mice1 (2009) (72)
T cell apoptosis and inflammatory bowel disease (2004) (71)
Thoracic duct in patients with multiple organ failure: no major route of bacterial translocation. (1999) (71)
Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. (1997) (70)
Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability-increasing protein. (1996) (70)
Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. (1993) (69)
Kinome analysis reveals nongenomic glucocorticoid receptor-dependent inhibition of insulin signaling. (2006) (69)
Upregulation of Monocyte Urokinase Plasminogen Activator Receptor during Human Endotoxemia (2000) (68)
Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma. (1997) (68)
Erythromycin Inhibits Tumor Necrosis Factor Alpha and Interleukin 6 Production Induced by Heat-Killed Streptococcus pneumoniae in Whole Blood (1998) (67)
Leptin signaling in human peripheral blood mononuclear cells, activation of p38 and p42/44 mitogen-activated protein (MAP) kinase and p70 S6 kinase. (2000) (67)
Intestinal endotoxemia. Clinical significance. (1988) (67)
Inflammatory and immunologic effects of obstructive jaundice: pathogenesis and treatment. (1995) (67)
Reduced Th1, but Not Th2, Cytokine Production by Lymphocytes after In Vivo Exposure of Healthy Subjects to Endotoxin (2000) (65)
Infliximab Treatment for Crohn's Disease: One-Year Experience in a Dutch Academic Hospital (2002) (64)
Interleukin 10 inhibits the release of CC chemokines during human endotoxemia. (2000) (63)
Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs (2019) (63)
Multiple signal transduction pathways regulate TNF-induced actin reorganization in macrophages: inhibition of Cdc42-mediated filopodium formation by TNF. (1999) (61)
In Vitro and In Vivo Down-Regulation of Regulatory T Cell Activity with a Peptide Inhibitor of TGF-β11 (2008) (59)
Feed a Cold, Starve a Fever? (2001) (59)
AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease (2017) (59)
Tumor Necrosis Factor Induces von Willebrand Factor Release in Healthy Humans (1992) (58)
Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies. (1995) (58)
A Single Oral Dose of Thalidomide Enhances the Capacity of Lymphocytes to Secrete Gamma Interferon in Healthy Humans (2000) (57)
Immunopathogenesis of IBD: insufficient suppressor function in the gut? (2006) (57)
Sonic hedgehog expression correlates with fundic gland differentiation in the adult gastrointestinal tract (2003) (56)
CXC-chemokines KC and macrophage inflammatory protein-2 (MIP-2) synergistically induce leukocyte recruitment to the central nervous system in rats. (2003) (56)
Intravenous infusion of erythromycin inhibits CXC chemokine production, but augments neutrophil degranulation in whole blood stimulated with Streptococcus pneumoniae. (2000) (55)
Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease. (1997) (55)
Interleukin-6, C-Reactive Protein, and Expression of Human Leukocyte Antigen-DR on Peripheral Blood Mononuclear Cells in Patients After Laparoscopic vs. Conventional Bowel Resection (2003) (54)
Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees. (1994) (54)
CXC chemokine receptor 2 contributes to host defense in murine urinary tract infection. (2001) (54)
Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy (2019) (54)
Cyclooxygenase‐dependent signalling: molecular events and consequences (1999) (53)
Perfusion-related factors of endotoxin release during cardiopulmonary bypass. (1994) (52)
In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs (2011) (52)
Lipopolysaccharide recognition, internalisation, signalling and other cellular effects. (2001) (51)
Expression of the chemokine receptors CXCR1 and CXCR2 on granulocytes in human endotoxemia and tuberculosis: involvement of the p38 mitogen-activated protein kinase pathway. (2000) (51)
Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. (2001) (51)
Endoscopic drainage aborts endotoxaemia in acute cholangitis (1996) (50)
Use of anti-tumour necrosis factor agents in inflammatory bowel disease (2001) (50)
Generation of regulatory gut-homing human T lymphocytes using ex vivo interleukin 10 gene transfer. (2002) (50)
Soluble Fc gamma receptor III (CD 16) and eicosanoid concentrations in gut lavage fluid from patients with inflammatory bowel disease: reflection of mucosal inflammation. (1996) (49)
Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. (1998) (49)
Feasibility of evaluating Crohn's disease activity at 3.0 Tesla (2006) (49)
Pharmacokinetics of 6-Thioguanine in Patients With Inflammatory Bowel Disease (2006) (49)
Serum concentrations of lipopolysaccharide activity-modulating proteins during tuberculosis. (1998) (49)
Successful treatment of metastatic Crohn disease with infliximab. (2002) (49)
Elevated levels of homocysteine increase IL-6 production in monocytic Mono Mac 6 cells. (2000) (48)
Procoagulant and proinflammatory activity in acute coronary syndromes. (1998) (48)
Mycobacterial lipoarabinomannan induces an inflammatory response in the mouse lung. A role for interleukin-1. (2000) (47)
Specific Inhibition of c-Raf Activity by Semapimod Induces Clinical Remission in Severe Crohn’s Disease1 (2005) (47)
Genomic structure of murine macrophage inflammatory protein-1 alpha and conservation of potential regulatory sequences with a human homolog, LD78. (1991) (46)
Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease (2019) (46)
Efficacy of recombinant granulocyte colony‐stimulating factor (rhG‐CSF) in experimental colitis (1996) (45)
Abrogation of IFN‐γ mediated epithelial barrier disruption by serine protease inhibition (2005) (45)
Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. (2001) (45)
Treatment and Prevention of Staphylococcus epidermidis Experimental Biomaterial-Associated Infection by Bactericidal Peptide 2 (2006) (45)
Differential Susceptibility of Multidrug Resistance Protein-1 Deficient Mice to DSS and TNBS-Induced Colitis (2002) (45)
The expanding role of biological agents in the treatment of inflammatory bowel disease – focus on selective adhesion molecule inhibition (2003) (45)
A prospective randomized study of hydrophilic polymer-coated polyurethane versus polyethylene stents in distal malignant biliary obstruction. (2003) (44)
Effects of IC14, an anti-CD14 antibody, on coagulation and fibrinolysis during low-grade endotoxemia in humans. (2003) (44)
Chemotactic activity of CXC chemokines interleukin-8, growth-related oncogene-alpha, and epithelial cell-derived neutrophil-activating protein-78 in urine of patients with urosepsis. (2000) (43)
Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23). (1995) (43)
Sequential Measurements of Chemokines in Urosepsis and Experimental Endotoxemia (1999) (42)
Polarised interleukin 8 secretion by HT 29/19A cells. (1994) (42)
Interleukin 8 released after acute myocardial infarction is mainly bound to erythrocytes (1997) (41)
Concurrent Upregulation of Urokinase Plasminogen Activator Receptor and CD11b during Tuberculosis and Experimental Endotoxemia (2001) (41)
Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia. (1994) (39)
Endogenous interferon-gamma impairs bacterial clearance from lungs during Pseudomonas aeruginosa pneumonia. (2001) (39)
DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. (2004) (38)
Patients with active tuberculosis have increased expression of HIV coreceptors CXCR4 and CCR5 on CD4(+) T cells. (2001) (37)
AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models (2019) (36)
The role of interferon-gamma in murine pneumococcal pneumonia. (2002) (36)
Immunotherapy of Crohn's disease. (1998) (34)
Neutralizing antibodies against adeno‐associated viruses in inflammatory bowel disease patients: Implications for gene therapy (2011) (34)
Infliximab Use in Children and Adolescents With Inflammatory Bowel Disease (2007) (34)
Lipopolysaccharide regulates macrophage fluid phase pinocytosis via CD14-dependent and CD14-independent pathways. (1999) (34)
Tumor necrosis factor (TNF) in inflammatory bowel disease: gene polymorphisms, animal models, and potential for anti-TNF therapy. (1995) (34)
Invited review: Lipopolysaccharide recognition, internalisation, signalling and other cellular effects (2001) (34)
Diarrhoea in HIV‐infected patients: no evidence of cytokine‐mediated inflammation in jejunal mucosa (1995) (33)
Immunohistochemical analysis of inflammation in primary sclerosing cholangitis (1998) (33)
Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients (2019) (33)
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future (2021) (33)
The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy. (2012) (33)
Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease (2019) (32)
Minimally Invasive Surgery Induces Endotoxin-Tolerance in the Absence of Detectable Endotoxemia (1998) (32)
Report on the Dutch Consensus Development Meeting for Implementation and Further Development of Population Screening for Colorectal Cancer Based on FOBT (2005) (32)
Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates. (2019) (31)
Impairment of host defence by exotoxin A in Pseudomonas aeruginosa pneumonia in mice. (2001) (31)
Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice. (2011) (31)
The effect of pseudomonas exotoxin A on cytokine production in whole blood exposed to Pseudomonas aeruginosa. (2000) (31)
Imaging of intestinal lymphocyte homing by means of pinhole SPECT in a TNBS colitis mouse model. (2004) (30)
Monocyte‐derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile (2007) (30)
Release of bactericidal/permeability-increasing protein in experimental endotoxemia and clinical sepsis. Role of tumor necrosis factor. (1996) (30)
Cysteinyl Leukotrienes Mediate Histamine Hypersensitivity Ex Vivo by Increasing Histamine Receptor Numbers (1999) (30)
Abrogation of IFN-gamma mediated epithelial barrier disruption by serine protease inhibition. (2005) (30)
Endotoxin‐induced mortality in bile duct—ligated rats after administration of reconstituted high‐density lipoprotein (2000) (29)
AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes (2019) (29)
Prevention of experimental colitis by parenteral administration of a pathogen-derived immunomodulatory molecule (2006) (28)
Treatment with recombinant bactericidal/permeability-increasing protein to prevent endotoxin-induced mortality in bile duct-ligated rats. (1999) (28)
Embedding siRNA sequences targeting Apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy (2012) (28)
Lexipafant (BB‐882), a platelet activating factor receptor antagonist, ameliorates mucosal inflammation in an animal model of colitis (1996) (28)
Anti- and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease. (2000) (28)
Dedicated pinhole SPECT of intestinal neutrophil recruitment in a mouse model of dextran sulfate sodium-induced colitis. (2005) (27)
Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. (2014) (26)
Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100 (2012) (26)
Macrophages Present Pinocytosed Exogenous Antigen Via MHC Class I Whereas Antigen Ingested by Receptor-Mediated Endocytosis Is Presented Via MHC Class II (2000) (26)
Rat ferritin-H: cDNA cloning, differential expression and localization during hepatocarcinogenesis. (1997) (26)
The role of phosphatidylinositide‐3‐kinase in basal mitogen‐activated protein kinase activity and cell survival (2000) (26)
Review article: targeting TNFα as a key cytokine in the inflammatory processes of Crohn’s disease — the mechanisms of action of infliximab (1999) (26)
Familial differences in endotoxin-induced TNF release in whole blood and peripheral blood mononuclear cells in vitro; relationship to TNF gene polymorphism (1995) (25)
Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. (2016) (24)
Review article: Chemokine production by intestinal epithelial cells: a therapeutic target in inflammatory bowel disease? (1997) (24)
Genetically Modified Lactococcus lactis for Delivery of Human Interleukin-10 to Dendritic Cells (2011) (24)
Anti-TNF antibody treatment of Crohn's disease (1999) (24)
Recombinant endotoxin-binding protein (rBPI23) attenuates endotoxin-induced circulatory changes in humans. (1995) (24)
Systemic inflammatory response in acute cholangitis and after subsequent treatment. (2000) (23)
Reduced ex vivo chemokine production by polymorphonuclear cells after in vivo exposure of normal humans to endotoxin. (2000) (23)
Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis? (1998) (23)
No increase in endotoxin release during antibiotic killing of meningococci. (1997) (23)
In vivo evaluation of 111In-labeled T-lymphocyte homing in experimental colitis. (2004) (23)
Anti-inflammatory effect of interleukin-10 in rabbit immune complex-induced colitis. (1998) (23)
Gene and cell therapy based treatment strategies for inflammatory bowel diseases. (2011) (23)
Endoscopic treatment of strictures in Crohn's disease. (2004) (23)
Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis. (2012) (22)
Comparison of the early dynamics of systemic prostacyclin release after administration of tumor necrosis factor and endotoxin to healthy humans. (1991) (22)
Activation of Mononuclear Cells by Interleukin-12: An In Vivo Study in Chimpanzees (1999) (22)
Inflammatory signal transduction in Crohn's disease and novel therapeutic approaches. (2002) (22)
Infliximab therapy in Crohn's disease: safety issues. (2003) (21)
Attenuation of the inflammatory response in an animal colitis model by neutrophil inhibitory factor, a novel beta 2-integrin antagonist. (1996) (21)
Widespread and sustained target engagement in Huntington’s disease minipigs upon intrastriatal microRNA-based gene therapy (2021) (21)
The role of interleukin-10 in the pathogenesis of bacterial infection. (1997) (21)
Endotoxins in portal blood. (1988) (21)
The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia. (1999) (21)
Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease. Relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans and in active Crohn's disease. (1998) (21)
Overexpression of prothymosin alpha, concomitant with c-myc, during rat hepatic carcinogenesis. (1997) (20)
Prevalence of subclinical anterior uveitis in adult patients with inflammatory bowel disease (2001) (20)
Endotoxin and tumor necrosis factor-alpha-induced interleukin-8 release in humans. (1993) (20)
An improved protocol for generation of immuno-potent dendritic cells through direct electroporation of CD14+ monocytes. (2007) (20)
Detection and clinical relevance of human endotoxemia. (1990) (19)
Urine Interleukin-8 Is a Marker for Urinary Tract Infection in Postoperative Patients (2001) (19)
Duodenal intraepithelial and lamina propria T lymphocytes in human immunodeficiency virus-infected patients with and without diarrhoea. (1996) (19)
CD4 antibody treatment in Crohn's disease. (1992) (19)
The Metalloproteinase Inhibitor GI5402 Inhibits Endotoxin-Induced Soluble CD27 and CD16 Release in Healthy Humans (2000) (19)
Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery (2020) (18)
Levels of Inhibitors of Tumor Necrosis Factor Alpha and Interleukin 1β in Urine and Sera of Patients with Urosepsis (1998) (18)
Mechanisms underlying neutrophil adhesion to apical epithelial membranes. (1996) (18)
In vivo interaction of endotoxin and recombinant bactericidal/permeability-increasing protein (rBPI23): hemodynamic effects in a human endotoxemia model. (2002) (18)
Inflammatory bowel disease and the genes for the natural resistance-associated macrophage protein-1 and the interferon-Á receptor 1 (1999) (18)
Induction of Cell-Associated Chemokines after Endotoxin Administration to Healthy Humans (2001) (18)
Cerebral Organoids: A Human Model for AAV Capsid Selection and Therapeutic Transgene Efficacy in the Brain (2020) (18)
Effect of interleukin 10 on the release of the CXC chemokines growth related oncogene GRO-alpha and epithelial cell-derived neutrophil activating peptide (ENA)-78 during human endotoxemia. (2001) (18)
A Coculture Model Mimicking the Intestinal Mucosa Reveals a Regulatory Role for Myofibroblasts in Immune-Mediated Barrier Disruption (2002) (18)
Correlation of repressed transcription of α‐tocopherol transfer protein with serum α‐tocopherol during hepatocarcinogenesis (1997) (18)
Clinical evaluation in febrile patients of an optimized endotoxin assay in blood. (1987) (17)
P38 Mitogen Activated Protein Kinase Is Involved in the Downregulation of Granulocyte CXC Chemokine Receptors 1 and 2 During Human Endotoxemia (2004) (17)
Study of calcium signaling in non‐excitable cells (1999) (17)
Muramyl dipeptide–induced differential gene expression in NOD2 mutant and wild‐type crohn's disease patient–derived dendritic cells (2008) (16)
The abnormal lipid spectrum in malignant obstructive jaundice in relation to endotoxin sensitivity and the result of preoperative biliary drainage. (2001) (16)
Enhanced Factor IX Activity following Administration of AAV5-R338L “Padua” Factor IX versus AAV5 WT Human Factor IX in NHPs (2019) (16)
Endotoxin down-regulates monocyte and granulocyte interleukin-6 receptors without influencing gp130 expression in humans. (2000) (16)
The cellular response in sepsis. (1996) (16)
Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease (2006) (15)
Disseminated intravascular coagulation: pathophysiology, diagnosis, and treatment. (1993) (15)
Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases. (1995) (14)
Activation of the Canonical β-Catenin Pathway by Histamine* (2003) (14)
Comparison of the early dynamics of coagulation activation after injection of endotoxin and tumor necrosis factor in healthy humans. (1991) (14)
Model for whole body production of tumour necrosis factor-alpha in experimental endotoxaemia in healthy subjects. (1994) (14)
Analysis of a Positional Candidate Gene for Inflammatory Bowel Disease: NRAMP2 (1999) (14)
Production and Cellular Source of Interleukin‐8 in Ulcerative Colitis (1995) (14)
Mediators of mucosal inflammation: implications for therapy. (1997) (13)
A place for TACE (2002) (13)
Thalidomide Inhibits Granulocyte Responses in Healthy Humans after Ex Vivo Stimulation with Bacterial Antigens (2001) (13)
Effect of IC14, an anti-CD14 antibody, on plasma and cell-associated chemokines during human endotoxemia. (2003) (12)
Lymph of patients with a systemic inflammatory response syndrome inhibits lipopolysaccharide-induced cytokine production. (1998) (12)
Endotoxemia, bacteremia and urosepsis. (1988) (12)
Anti‐CD4 Therapy Decreases Epithelial Expression of HLA‐DR Molecules in Patients with Crohn’s Disease (1995) (12)
Endotoxin-induced neutrophil activation--the role of complement revisited. (1991) (12)
Thalidomide suppresses Up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4+ T cells in humans. (2000) (12)
Anti-tumour necrosis factor therapy in Crohn’s disease: where are we now? (2002) (12)
Endotoxin induced coagulation activation and protein C reduction in meningococcal septic shock. (1994) (11)
Targeting tumor necrosis factor‐&agr; in inflammatory bowel disease: why, how, and when? (2003) (11)
Correlation between early recurrence and reoperation after ileocolonic resection in Crohn's disease: a prospective study. (1996) (11)
Granulocyte colony-stimulating factor receptors on granulocytes are down-regulated after endotoxin administration to healthy humans. (2000) (11)
Murine CD4+CD25- cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo (2012) (11)
Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver (2013) (10)
Cytokines and host defense in pneumonia (1999) (10)
Pathogenesis of DIC in Sepsis (1999) (10)
Factors involved in early in vitro endotoxin hyporesponsiveness in human endotoxemia (1996) (10)
Monoclonal antibody therapy of inflammatory bowel disease. (1997) (9)
New biological therapies in inflammatory bowel disease. (2003) (9)
Inflammatory bowel disease and the genes for the natural resistance-associated macrophage protein-1 and the interferon-gamma receptor 1. (1999) (9)
Endotoxin-induced cytokines in human septicemia. (1990) (8)
In situ detection of interleukin-1 beta and interleukin 8 in biopsy specimens from patients with ulcerative colitis. (1995) (8)
Interleukin 10 Release During Endotoxaemia in Chimpanzees: Role of Platelet‐Activating Factor and Interleukin 6 (1996) (8)
Role of Endogenous Interleukin-12 in Immune Response to Staphylococcal Enterotoxin B in Mice (2001) (8)
The role of interleukin 6 in endotoxin-induced inflammatory responses. (1998) (8)
IL-10 Producing Lactococcus lactis for the Treatment of Crohn's Disease (2006) (7)
Correlation of repressed transcription of alpha-tocopherol transfer protein with serum alpha-tocopherol during hepatocarcinogenesis. (1997) (7)
Increase of sTNF receptor levels in acute renal allograft rejection after treatment with OKT3. (1994) (6)
Interleukin-1 alpha expression is inducible by cholinergic stimulation in the rat adrenal gland. (1992) (6)
Neutrophil adhesion molecules and MOF (1997) (6)
Taming the mucosal immune response in Crohn's disease. (2002) (6)
A patient with hereditary hemochromatosis, ulcerative colitis, and primary sclerosing cholangitis: genetic aspects. (2001) (6)
[Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients]. (1993) (5)
[Immunology in medical practice. IV. Inflammatory bowel diseases: pathogenic starting points for specific therapy]. (1997) (5)
Regulatory T cells as potential targets for immunotherapy in inflammatory bowel disease. (2010) (5)
Immunomodulation of Crohn's Disease. (2000) (4)
Elevated Lipoprotein(a) in Perinatally HIV-Infected Children Compared With Healthy Ethnicity-Matched Controls (2019) (4)
Endotoxin and the release of tumor necrosis factor receptors. (1994) (4)
Divergent Roles of Tumor Necrosis Factor and Platelet-Activating Factor in Endotoxin-Induced Release of Monocyte Chemoattractant Protein 1 and Macrophage Inflammatory Protein 1β in Chimpanzees (1999) (4)
Therapy of gram-negative sepsis in man with anti-endotoxin antibodies: a review. (1991) (4)
LPS induced translocation of NF-κB occurs only in a subpopulation of CD14-positive mononuclear cells (1999) (4)
The drug treatment of crohn’s disease (1986) (4)
Inhibition of extrinsic coagulation activation in endotoxemia; therapeutic implications. (1994) (3)
[Current developments in the field of sepsis: tumor necrosis factor (cachectin)]. (1989) (3)
Known bacterial virulence factors do not explain the variation in urinary cytokine levels in patients with urosepsis. (1996) (3)
Drainage of the gallbladder in patients with acute acalculous cholecystitis by transpapillary endoscopic cholecystoxeransis. (1994) (3)
PhP.B Enhanced Adeno-Associated Virus Mediated-Expression Following Systemic Delivery or Direct Brain Administration (2021) (3)
Is G-CSF safe and useful in the treatment of infectious diseases in the non-neutropenic host? (1997) (3)
The future of inflammatory bowel disease therapy. (2002) (3)
Inflammatory Bowel Disease: Future Therapies. (2002) (3)
The role of tumor necrosis factor in systemic inflammatory responses in primate endotoxemia. (1994) (2)
Use of buffered formaldehyde in the enzymatic digestion of inflamed mucosa. (1996) (2)
[Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis]. (1993) (2)
Increased levels of sTNF receptors following OKT3 treatment. (1994) (2)
[Role of mucins in inflammatory intestinal diseases]. (1994) (2)
Immunotherapy of gram-negative septicemia. (1991) (1)
Erythrocyte-bound interleukin-8 and RANTES in human endotoxemia (1997) (1)
Human thoracic duct lymph inhibits lipopolysaccharide-induced release of cytokines (1997) (1)
Protection Against Experimental Colitis by Filamentous Hemagglutinin A of Bordetella pertussis Is Not Exclusively Mediated by Interleukin-10 (2006) (1)
[Chlamydia pneumoniae as a causative agent in atherosclerosis]. (1999) (1)
Immunomodulation of Crohn's disease using TNF-alpha neutralizing monoclonal antibodies. (1997) (1)
Video autofluorescence imaging (AFI) followed by narrow band imaging (NBI) for detection of high grade dysplasia (HGD) and early cancer (EC) in barrett's esophagus (BE) (2005) (1)
[Immunology in clinical practice. VIII. Role of cytokines in the pathogenesis of bacterial infections]. (1998) (1)
Gastrointestinal permeability in cardiac surgery patients, the interpretation of dual-sugar absorption studies. (1997) (1)
[Atherosclerosis partly due to local vasculitis]. (1994) (1)
Mucosal Delivery of Ovalbumin by the Genetically Modified Lactococcus lactis Suppresses T Cell Responses in DO11.10 Mice (2006) (1)
[Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo]. (1993) (1)
[Monoclonal anti-endotoxin antibodies in the treatment of patients with sepsis due to Gram-negative bacteria]. (1991) (1)
Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents (2021) (1)
Overlapping Gene Expression Profiles of Experimental Colitis and IBD (2006) (1)
Glucocorticoid-induced Inhibition of T Cell Receptor Signaling Mediated Through Lck and Fyn: A New Mechanism for an Old Drug (2006) (1)
Cytokines and mucosal inflammatory response in Crohn's disease. (1998) (1)
[Why is immune therapy in sepsis unsuccessful?]. (1995) (0)
Biological therapies of inflammatory bowel disease. (2001) (0)
Endoscopic drainage aborts endotoxaemia in acute cholangitis. (1996) (0)
Plasma and lymph of patients with and without multiple organ failure inhibit endotoxin‐induced cytokine release (1998) (0)
[Acute kidney function disorders caused by nonsteroidal anti-inflammatory agents]. (1986) (0)
Obituary JW ten Cate. (2021) (0)
Antibody to endotoxin in the treatment of gram-negative sepsis. (1992) (0)
[Treatment of a renal artery occluded by an embolism with low-dose streptokinase]. (1985) (0)
Pharmacological modulation of the acute phase response in experimental colitis (1994) (0)
Small therapeutic molecules for the treatment of inflammatory bowel disease (2002) (0)
[Immunotherapy in sepsis syndrome]. (1992) (0)
[Current developments in the field of infection caused by gram-negative microorganisms; passive immunization using anti-endotoxin antibodies]. (1987) (0)
[Activated protein C, coagulation, inflammation, and treatment of severe sepsis]. (2001) (0)
[The role of cytokines in the pathogenesis of inflammatory intestinal diseases]. (1994) (0)
[Pharmacotherapeutic compass 1998]. (1998) (0)
M01 Rnai-based Gene Therapy Of Huntington’s Disease (2014) (0)
The thoracic duct is not a major route of bacterial translocation in patients with multiple organ failure (1998) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Sander J. H. Van Deventer?

Sander J. H. Van Deventer is affiliated with the following schools:

University of Amsterdam